True North Therapeutics Garners Series A Funding

  • Feed Type
  • Date
  • Company Name
    True North Therapeutics
  • Mailing Address
    951 Gateway Blvd South San Francisco, CA 94080
  • Company Description
    True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The Series A financing will be used to advance its lead drug candidate TNT009, a first-in-class monoclonal antibody that selectively inhibits a target of the Classical Complement pathway, into clinical trials.
  • M&A Terms
  • Venture Investor
    SR One
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    MPM Capital

Trending on Xconomy